Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iloprost
- Development stage
- Approved
- Lead developer
- Bayer HealthCare Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Inhalation, Intravenous
01
Overview
Iloprost is a synthetic analog of prostacyclin (PGI2), classified as a vasodilator. It is primarily used to treat pulmonary arterial hypertension (PAH) by relaxing blood vessels in the lungs, improving exercise capacity, and slowing symptom progression. Iloprost also inhibits platelet aggregation and has cytoprotective effects in ischemic tissues. In addition to PAH, it is approved for severe frostbite to reduce the risk of digit amputation and is used off-label for conditions such as Raynaud's phenomenon and scleroderma-related vascular complications. Iloprost can be administered via inhalation or intravenous infusion depending on indication[1][2][3][4][5].
- Brand names
- VentavisAurlumyn
- Other names
- iloprost
02
Targets
PTGER1 (Prostaglandin E Receptor 1)PTGER3 (Prostaglandin E2 receptor EP3 subtype)PTGIR (Prostanoid IP Receptor)PTGER2 (Prostaglandin E2 receptor EP2)PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on iloprost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iloprost.